Fiscal Year Ending December 2026 Q1 Consolidated Financial Results [IFRS] Supplementary Materials

Performance Overview

In the Q1 consolidated financial results for the fiscal year ending December 2026, revenue reached 321.7 billion yen, an 11.5% increase compared to the same period of the previous year. Product sales amounted to 291.6 billion yen (up 12.3% YoY), with domestic sales at 111.4 billion yen (up 8.2% YoY) and overseas sales at 180.1 billion yen (up 14.9% YoY), both showing steady growth. Operating income was 158.8 billion yen (up 16.2% YoY), and net income attributable to owners of parent was 115.4 billion yen (up 18.7% YoY), reflecting earnings growth alongside revenue expansion. The operating margin based on Core results remained high at approximately 50.8%, and R&D expenses accounted for 13.0% of revenue.

Business Segments and Development Pipeline Status

Oncology sales grew to 55.7 billion yen (up 4.9% YoY) while Specialty segment sales reached 55.7 billion yen (up 11.6% YoY). Overseas sales expanded primarily driven by co-developed products with Roche, especially Hemlibra, whose overseas sales surged to 108.9 billion yen (up 26.3% YoY). Several new drugs in the development pipeline are currently under regulatory review or in Phase III trials, with active progress mainly in oncology and immunology therapeutic areas.